Ken Griffin Kymera Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	BUY	$22.9 - $43.57 $36,640 - $69,712	1,600 Added 19.75%	9,700 $389,000
Q4 2023 Feb 14, 2024	BUY	$10.97 - $26.84 $44,977 - $110,044	4,100 Added 102.5%	8,100 $206,000
Q3 2023 Nov 14, 2023	BUY	$13.9 - $23.88 $25,020 - $42,984	1,800 Added 81.82%	4,000 $55,000
Q2 2023 Aug 14, 2023	SELL	$22.4 - $34.92 $2,240 - $3,492	-100 Reduced 4.35%	2,200 $50,000
Q1 2023 May 15, 2023	SELL	$24.84 - $38.75 $1.54 Million - $2.4 Million	-62,000 Reduced 96.42%	2,300 $68,000

Q4 2022 Feb 14, 2023	BUY	$19.57 - $30.92 $970,672 - $1.53 Million	49,600 Added 337.41%	64,300 $1.6 Million
Q3 2022 Nov 14, 2022	BUY	$20.91 - $34.27 $307,377 - $503,769	14,700 New	14,700 $320,000

164

63.1M

39.7K

9.7K

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $1.65B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.